Non-steroidal Anti-inflammatory Drugs Market Introduction and Overview
According to SPER Market Research, the Global Non-steroidal Anti-inflammatory Drugs Market is estimated to reach USD 40.44 billion by 2034 with a CAGR of 5.92%.
The report includes an in-depth analysis of the Global Non-steroidal Anti-inflammatory Drugs Market, including market size and trends, product mix, Applications, and supplier analysis. The global non-steroidal anti-inflammatory medicines market was valued at USD 22.75 billion in 2024 and is predicted to increase at a CAGR of 5.92% between 2025 and 2034. The global increase in chronic pain prevalence and the growing geriatric population are driving the expansion of the nonsteroidal anti-inflammatory medication (NSAID) market. Increased demand for over-the-counter NSAIDs, as well as expanded usage in illnesses such as headaches, migraines, toothaches, and menstruation pain, contribute to growth estimates. Furthermore, a diversified NSAID product range, as well as new product approvals and launches, help to drive market momentum during the projection period.
By Disease Indication Insights: The arthritis segment led the non-steroidal anti-inflammatory drugs industry, holding the largest revenue share in 2024 due to the rise in arthritis cases and an aging population. More treatment options, like NSAIDs and biologics, along with increased awareness and advances in treatments, have strengthened this segment. Companies are also focusing on new product development for arthritis patients' needs.
By Route of Administration Insights: The oral segment led the market and had the highest revenue share in 2024 because of its convenience and effectiveness in delivering medications. Both patients and healthcare providers prefer oral administration for its ease of use, adherence, and versatility in treatment. The increasing demand for OTC pain relief and prescription medications boosts this segment's growth, supported by better drug formulation technology.
By Distribution Channel Insights: The retail pharmacy segment led the non-steroidal anti-inflammatory drugs industry, capturing the largest revenue share in 2024. This dominance results from its broad distribution network and accessibility to consumers. The rise in over-the-counter medication demand and self-medication trends, along with a wide range of products and convenience, enhance customer satisfaction. Chronic diseases also increase the need for ongoing medication.
By Regional Insights: North America dominated the global non-steroidal anti-inflammatory medicines industry, accounting for a sizable revenue share in 2024; the sector is predicted to develop significantly, affected by a number of major variables. A vast number of manufacturers and prominent companies' strategic endeavors are driving market growth.
Market Competitive Landscape:
The competitive landscape in the NSAIDs sector is defined by the existence of numerous important firms, including Pfizer, Bayer, and Johnson & Johnson, each of whom offers a variety of products to address varied customer needs. Market strategies revolve around innovation, pricing, and distribution methods. Companies spend in R&D to produce new formulations and combination medicines. Generic brands, which provide cost-effective alternatives, are likewise becoming more competitive on the market. Regulatory compliance and quality assurance are still crucial for sustaining market position. Collaborations and partnerships improve distribution capability and market reach.
Recent Developments:
- In April 2024, Glenmark Pharmaceuticals received U. S. FDA approval for its Acetaminophen and Ibuprofen Tablets (250 mg/125 mg), now an OTC product. This product is similar to Haleon’s Advil Dual Action, which earned around USD 84.1 million in sales last year. Glenmark has 195 products approved in the U. S. and 52 ANDAs pending, focusing on respiratory, dermatology, and oncology areas while operating 11 manufacturing facilities globally.
- In December 2023, Scilex Holding Company submitted a New Drug Submission to Health Canada for ELYXYB (celecoxib oral solution) to treat acute migraines. ELYXYB is the only FDA-approved ready-to-use oral solution for migraines, relieving pain in 15 minutes. The Canadian migraine market is expected to reach USD 400 million by 2025, with approval anticipated in 12 months. Scilex aims to offer options for patients not responding to triptan therapies.
- In May 2023, AbbVie Inc received FDA approval for RINVOQ (upadacitinib) to treat adults with moderately to severely active Crohn’s disease, which is expected to improve its anti-inflammatory drug offerings and revenue growth.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Disease Indication, By Route of Administration, By Distribution Channel. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Pfizer Inc, Bayer AG, GSK plc, Dr. Reddys Laboratories Ltd, Viatris Inc, Teva Pharmaceutical Industries Ltd, Johnson and Johnson Services, Merck & Co, Inc. and others. |
Key Topics Covered in the Report:
- Global Non-steroidal Anti-inflammatory Drugs Market Size (FY’2021-FY’2034)
- Overview of Global Non-steroidal Anti-inflammatory Drugs Market
- Segmentation of Global Non-steroidal Anti-inflammatory Drugs Market By Disease Indication (Arthritis, Migraine, Ophthalmic Diseases, Others)
- Segmentation of Global Non-steroidal Anti-inflammatory Drugs Market By Route of Administration (Oral, Topical, Others)
- Segmentation of Global Non-steroidal Anti-inflammatory Drugs Market By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
- Statistical Snap of Global Non-steroidal Anti-inflammatory Drugs Market
- Expansion Analysis of Global Non-steroidal Anti-inflammatory Drugs Market
- Problems and Obstacles in Global Non-steroidal Anti-inflammatory Drugs Market
- Competitive Landscape in the Global Non-steroidal Anti-inflammatory Drugs Market
- Details on Current Investment in Global Non-steroidal Anti-inflammatory Drugs Market
- Competitive Analysis of Global Non-steroidal Anti-inflammatory Drugs Market
- Prominent Players in the Global Non-steroidal Anti-inflammatory Drugs Market
- SWOT Analysis of Global Non-steroidal Anti-inflammatory Drugs Market
- Globa Non-steroidal Anti-inflammatory Drugs Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Non-steroidal Anti-inflammatory Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Non-steroidal Anti-inflammatory Drugs Market
7. Global Non-steroidal Anti-inflammatory Drugs Market, By Disease Indication (USD Million) 2021-2034
7.1. Arthritis
7.2. Migraine
7.3. Ophthalmic Diseases
7.4. Others
8. Global Non-steroidal Anti-inflammatory Drugs Market, By Route of Administration (USD Million) 2021-2034
8.1. Oral
8.2. Topical
8.3. Others
9. Global Non-steroidal Anti-inflammatory Drugs Market, By Distribution Channel (USD Million) 2021-2034
9.1. Hospital Pharmacy
9.2. Retail Pharmacy
9.3. Online Pharmacy
10. Global Non-steroidal Anti-inflammatory Drugs Market, (USD Million) 2021-2034
10.1. Global Hospital Pharmacy
10.2. Retail Pharmacy
10.3. Online Pharmacy Market Size and Market Share
11. Global Non-steroidal Anti-inflammatory Drugs Market, By Region, (USD Million) 2021-2034
11.1. Asia-Pacific
11.1.1. Australia
11.1.2. China
11.1.3. India
11.1.4. Japan
11.1.5. South Korea
11.1.6. Rest of Asia-Pacific
11.2. Europe
11.2.1. France
11.2.2. Germany
11.2.3. Italy
11.2.4. Spain
11.2.5. United Kingdom
11.2.6. Rest of Europe
11.3. Middle East and Africa
11.3.1. Kingdom of Saudi Arabia
11.3.2. United Arab Emirates
11.3.3. Qatar
11.3.4. South Africa
11.3.5. Egypt
11.3.6. Morocco
11.3.7. Nigeria
11.3.8. Rest of Middle-East and Africa
11.4. North America
11.4.1. Canada
11.4.2. Mexico
11.4.3. United States
11.5. Latin America
11.5.1. Argentina
11.5.2. Brazil
11.5.3. Rest of Latin America
12. Company Profile
12.1. Pfizer Inc
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Bayer AG
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. GSK plc
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Dr. Reddys Laboratories Ltd
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. Viatris Inc
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Teva Pharmaceutical Industries Ltd
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Johnson and Johnson Services, Inc
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Merck & Co., Inc
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
